Q-omics provides the consensus-scored CSTF2T profile across patient tissues and cancer cell-line models. CSTF2T expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CSTF2T is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, CSTF2T RNA expression shows 20,319 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where CSTF2T shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSTF2T — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSTF2T survival associations across molecular data types. CSTF2T RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSTF2T RNA expression–survival associations across cancer types. High CSTF2T expression shows unfavorable associations in ACC and LIHC, but favorable associations in KIRC, MESO, LGG and STAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CSTF2T RNA expression.
This table summarizes CSTF2T tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CSTF2T. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSTF2T shows lower tumor expression in THCA, KICH and BLCA and higher tumor expression in LIHC, CHOL and HNSC. The THCA box plot shows higher CSTF2T RNA expression in normal versus tumor tissue (log2 FC = −0.742, t-test p < 0.001).
This table shows molecular features associated with CSTF2T in patient tissues and cancer cell lines. In patient samples, CSTF2T shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CSTF2T RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
